Insight Molecular Diagnostics Inc.
NASDAQ:IMDXMedical - Diagnostics & Research
+$0.13 today
- Market cap
- $52.08M
- Beta
- 1.79
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.39
Volume 0.64M
Average 0.38M
IMDX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Insight Molecular Diagnostics Inc.NASDAQ: IMDX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns positive
Q1 FY2026 accounts receivables was $971K, compared with -$1.93M a year earlier. Trailing-twelve-month accounts receivables was $3.38M.
Context
- Accounts receivables amounted to 12.0% of revenue in FY2025, down 48.1 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near $971K or moves back toward the trailing-twelve-month quarterly average of $845.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 485K USD
- Year-over-year change
- +143.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 485K | +143.0% |
| FY2024 | 2024-12-31 | (1.13M) | -1135.8% |
| FY2023 | 2023-12-31 | 109K | +119.0% |
| FY2022 | 2022-12-31 | (575K) | +53.2% |
| FY2021 | 2021-12-31 | (1.23M) | — |
Accounts Receivables vs competitors
How IMDX compares with its peers on the latest reported figures
- IMDX's LTM Mar 2026 accounts receivables of $3.38M is the 6th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of +200.1% is the 3rd highest of 7, against a peer median of +16.3%.
- Accounts receivables amounts to 173.6% of revenue for IMDX, versus a peer median of 8.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $5.15M | -7.6% | -45.1% | 14.8% | |
| LTM Mar 2026 | $4.26M | +247.4% | — | 14.7% | |
| LTM Mar 2026 | $4.02M | +18.0% | -59.5% | 11.6% | |
| LTM Mar 2026 | $3.56M | +14.6% | — | 4.6% | |
| LTM Mar 2026 | $3.46M | -39.0% | — | 6.2% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.38M | +200.1% | — | 173.6% |
| LTM Mar 2026 | $2.85M | +7601.5% | +15.2% | 159.7% | |
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding IMDX) | $0 | +16.3% | -45.1% | 8.9% | |
Competitors are the stored peer set for IMDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (64.1M) | (72.9M) | (27.78M) | (60.66M) | (50.22M) |
| Depreciation & Amortization | 4.21M | 5.22M | 1.68M | 1.56M | 2.2M |
| Deferred Income Tax | (9.26M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.84M | 10.04M | 6.57M | 1.91M | 2.22M |
| Change in Working Capital | 149K | (1.94M) | (3.97M) | (1.32M) | 2.73M |
| Accounts Receivables | (1.23M) | (575K) | 109K | (1.13M) | 485K |
| Inventory | 0 | 0 | 0 | (410K) | (36K) |
| Accounts Payables | (1.35M) | 297K | (4.76M) | 967K | 2.65M |
| Other Working Capital | 2.73M | (1.66M) | 677K | (749K) | (368K) |
| Other Non-Cash Items | 26.22M | 14.01M | 174K | 37.79M | 20.9M |
| Operating Cash Flow | (35.94M) | (45.57M) | (23.33M) | (20.71M) | (22.18M) |
| Capital Expenditures | (2.25M) | (4.34M) | (281K) | (516K) | (3.19M) |
| Acquisitions (Net) | (11.71M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 367K | 0 | 0 |
| Other Investing Activities | 0 | 0 | (1.02M) | 4K | 0 |
| Investing Cash Flow | (13.96M) | (4.34M) | (932K) | (512K) | (3.19M) |
| Debt Repayment | (1.53M) | (1.43M) | (117K) | (201K) | (510K) |
| Common Stock Issued | 77.99M | 32.84M | 13.85M | 27.81M | 28.66M |
| Common Stock Repurchased | (239K) | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.15M | (483K) | (427K) | (1.8M) | (74K) |
| Financing Cash Flow | 78.36M | 35.81M | 12.19M | 20.43M | 28.07M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 973K |
| Net Change in Cash | 28.46M | (14.1M) | (12.07M) | (796K) | 3.68M |
| Free Cash Flow | (38.19M) | (49.91M) | (23.61M) | (21.23M) | (25.37M) |
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
Intrinsic Alpha fair value
Locked
Current Price
$1.59
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.